Report: Transfer and Discharge Deficiencies Cited Since 2017: Surveyors Focus On paperwork, Not Residents’ Rights Study Finds Link Between Registered Nurse Hours and Antipsychotic Drug Use Webinar: Skilled Nursing Facilities … [Read more...] about CMA Alert – SNF Updates – Report: Transfer & Discharge Deficiencies; Link Between Nurse Hours and Antipsychotics; Webinar Next Week
Search Results for: antipsychotics
Letter to Inspector General Regarding Suspension of Antipsychotics Investigation
July 26, 2013 Daniel R. Levinson Inspector General Department of Health and Human Services 330 Independence Avenue, SW Washington, DC 20201 Submitted Electronically Dear Mr. Levinson: A report today that your office has … [Read more...] about Letter to Inspector General Regarding Suspension of Antipsychotics Investigation
Toby Edelman Testifies Before Senate Special Committee Regarding Antipsychotics In Nursing Homes
UNITED STATES SENATE SPECIAL COMMITTEE ON AGING OVERPRESCRIBED: THE HUMAN AND TAXPAYERS' COSTS OF ANTIPSYCHOTICS IN NURSING HOMES November 30, 2011 Testimony of Toby S. Edelman Senior Policy Attorney Center for Medicare Advocacy The … [Read more...] about Toby Edelman Testifies Before Senate Special Committee Regarding Antipsychotics In Nursing Homes
CMA Alert | October 21, 2022
CMA Report | Privatization of County-Owned Nursing Facilities is Not Good for Residents, Staff, or States In a May 1, 1998 report entitled “Nursing Home Privatization: What Is the Human Cost?”[1] the Pennsylvania-based Keystone Research Center … [Read more...] about CMA Alert | October 21, 2022
Study | Black Nursing Home Residents Disproportionately (and Incorrectly) Diagnosed with Schizophrenia
The COVID-19 pandemic highlighted deeply rooted racial and ethnic health disparities nationwide[1] – particularly within the walls of U.S. nursing homes. Nursing homes with a larger proportion of Black and Hispanic residents reported more deaths and … [Read more...] about Study | Black Nursing Home Residents Disproportionately (and Incorrectly) Diagnosed with Schizophrenia
CMA Alert | May 13, 2021
New Factsheet | CMS Nursing Home Visitation Guidance According to the Centers for Disease Control and Prevention (CDC), as of May 3, 2021 the number of confirmed nursing home resident cases has fallen to 0.99 cases per 1,000 residents. This is … [Read more...] about CMA Alert | May 13, 2021
HHS Inspector General Finds CMS Data Understates Antipsychotic Drug Use in Nursing Homes
A serious and longstanding quality of care problem in nursing homes is the inappropriate use of antipsychotic drugs with residents who have dementia. A decade ago, the HHS Office of Inspector General (OIG) reported that 83% of claims for … [Read more...] about HHS Inspector General Finds CMS Data Understates Antipsychotic Drug Use in Nursing Homes
Transition Memorandum for Biden Administration Department of Health & Human Services (HHS)
December 2020 Links to detailed sections below I. Introduction II. Executive Summary: Administrative Measures III. Medicare Platform: Legislative Agenda IV. Administrative Action: Full Recommendations Strengthen Protections for Nursing … [Read more...] about Transition Memorandum for Biden Administration Department of Health & Human Services (HHS)
CMA Alert – October 17, 2019
Center for Medicare Advocacy Board President Judith Feder Testifies at Drug Pricing Hearing Administration’s “Public Charge” Rule [Temporarily?] Blocked Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing … [Read more...] about CMA Alert – October 17, 2019
Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing Home Residents to Pay Over $115 Million
Background When the Centers for Medicare & Medicaid Services (CMS) launched a national campaign to reduce the off-label prescribing of antipsychotic drugs for nursing home residents in 2012, Avanir Pharmaceuticals directed its sales force to … [Read more...] about Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing Home Residents to Pay Over $115 Million